Form 4: Phibro Animal Health CEO Sells Shares, Converts Stock

Phibro Animal Health's President and CEO, Jack Bendheim, reported the sale of 1,235 Class A common shares and the conversion of 30,000 Class B shares into Class A common shares.

Summary

• Jack Bendheim, President and CEO of Phibro Animal Health Corp, and BFI Co., LLC, reported transactions involving the company's equity securities.
• On January 23, 2026, BFI Co., LLC sold 1,235 shares of Class A Common Stock at a weighted average price of $40.5538 per share, with prices ranging from $40.175 to $41.01.
• This sale was executed under a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.
• Following this sale, BFI Co., LLC indirectly beneficially owned 15,445 shares of Class A Common Stock.
• On January 26, 2026, BFI Co., LLC converted 30,000 shares of Class B Common Stock into 30,000 shares of Class A Common Stock.
• Class B Common Stock is convertible into Class A Common Stock on a one-for-one basis at any time, with no expiration date.
• After the conversion, BFI Co., LLC indirectly beneficially owned 45,445 shares of Class A Common Stock and 19,911,034 shares of Class B Common Stock (derivative).
• Jack Bendheim directly holds 16,840 shares of Class A Common Stock.
• Mr. Bendheim exercises voting and dispositive power over BFI Co., LLC and disclaims beneficial ownership of BFI's securities except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there is an insider sale, it was conducted under a pre-arranged 10b5-1 plan, which mitigates the negative perception often associated with insider selling. The conversion of Class B to Class A stock is a routine corporate action.

Positives

• The sale of shares was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned transaction rather than an immediate reaction to new information.
• The conversion of Class B to Class A stock increases the liquidity of the converted shares.

Negatives

• An insider sale of 1,235 shares by a significant shareholder (BFI Co., LLC, controlled by the CEO) could be perceived negatively by some investors, even if pre-planned.

Future Outlook

NA

Industry Context

This Form 4 filing details insider transactions and does not provide information relevant to broader industry trends or competitive analysis.

Related Party Transactions

• The transactions involve BFI Co., LLC, which is controlled by Jack Bendheim, a director, 10% owner, and President and CEO of Phibro Animal Health Corp. Mr. Bendheim disclaims beneficial ownership of BFI's securities except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders may view the insider sale, even if pre-planned, with some scrutiny, though the relatively small number of shares sold compared to total holdings might limit significant concern.
• The conversion of Class B to Class A stock could slightly increase the float of Class A shares, potentially impacting liquidity for Class A shareholders.

Key Dates

Recommendation

The filing reports routine insider transactions, including a sale under a 10b5-1 plan and a conversion of Class B to Class A stock. While insider selling can sometimes be a negative signal, the pre-planned nature of the sale mitigates immediate concerns. The conversion is a standard corporate action. Without additional financial or operational context, these transactions alone do not warrant a change from a 'hold' position, as they do not fundamentally alter the company's investment thesis.

Keywords

Phibro Animal Health, PAHC, SEC Form 4, Insider Trading, Stock Sale, Class A Common Stock, Class B Common Stock, Stock Conversion, Jack Bendheim, BFI Co., LLC, Rule 10b5-1 Plan, Corporate Governance